May 13, 2015
Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform
May 7, 2015
Evidence of efficacy of gene therapy in rodents affected by a rare genetic liver disease, Crigler-Najjar syndrome
April 21, 2015
New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome
November 10, 2014
Effectiveness of innovative gene therapy treatment demonstrated in canine model of Duchenne muscular dystrophy
March 11, 2014
GENETHON and ESTEVE announce agreement to manufacture the gene therapy for the treatment of Sanfilippo Syndrome
February 5, 2014
Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X‐Linked Myotubular Myopathy
January 23, 2014
Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy
June 27, 2013
Généthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer
June 24, 2013
The European charity Myotubular Trust is supporting Généthon in developing gene therapy for myotubular myopathy
February 5, 2013
Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease
November 8, 2012
Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!
September 27, 2012
Genethon, member of the Biotherapies Institute for Rare Diseases
The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre). (read more)
July 4, 2012
Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod
Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. (read more)
